Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

9.87
-0.2400-2.37%
Post-market: 9.870.00000.00%16:13 EDT
Volume:263.57K
Turnover:2.61M
Market Cap:454.95M
PE:-3.34
High:10.05
Open:10.01
Low:9.72
Close:10.11
Loading ...
Mar 21, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Mar 21, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 21, 2022

Major Issues Report

8-K - Current report
Mar 08, 2022

Major Issues Report

8-K - Current report
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 04, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 02, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Dec 02, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 02, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Oct 28, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Aug 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 04, 2021

Major Issues Report

8-K - Current report
Jul 14, 2021

Major Issues Report

8-K - Current report
Jun 08, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 18, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 18, 2021

Major Issues Report

8-K - Current report